



Financial Results for the 1st Quarter of the Fiscal Year Ending March 31, 2011


August 3, 2010

Sysmex Corporation

Forward-looking Statements

This material contains forward-looking statements about Sysmex Corporation and its group companies (the Sysmex Group). These forward-looking statements are based on the current judgments and assumptions of the Sysmex Group in light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our business operations, and changes in operating environment both in Japan and overseas may cause our actual results, performance, achievements, or financial position to be materially different from any future results, performance, achievements, or financial position either expressed or implied within these forward-looking statements.

1st Quarter Financial Highlights



(First Quarters Ended June 30)

	FY2011 1Q		FY2010 1Q		% over a Year Earlier
		Ratio		Ratio	
Net Sales	27.8	100%	24.9	100%	111.6%
Operating Income	3.3	12.1%	1.6	6.5%	207.1%
Ordinary Income	3.0	10.8%	1.7	7.1%	169.4%
Net Income	1.7	6.3%	1.1	4.5%	157.7%

(Billions of yen)

Despite the negative effects of yen appreciation, significant growth in the Americas and China led to record levels of sales and income.

- ▶ Sales and income increased in all geographic regions on a local currency basis, including Japan.
- ▶ Operating income advanced, owing to significantly increased income in the Americas and China.
- ▶ The non-operating balance was a negative ¥0.37 billion (of which, forex loss amounted to ¥0.46 billion)
- ▶ Yen appreciation reduced net sales ¥1.4 billion and operating income ¥0.41 billion.

Notes: At the exchange rates prevailing one year earlier, net sales would have been up 17.5% year on year, and operating income up 132.9%.

Capital expenditure: ¥1.0 billion; Depreciation and amortization: ¥1.8 billion;

R&D expenditure: ¥2.9 billion

(Yen)

	FY2011 1Q	FY2010 1Q
1US\$	92.0	97.3
1EUR	117.0	132.6

Note: Assumed exchange rates for the fiscal year ending March 31, 2011 are US\$1.00 = ¥90 and €1,00 = ¥125

Breakdown of Net Sales and Operating Income





(Billions of yen)

Net Sales

Operating Income

Note: FX impact excluded from regional sales below

Gross margin increased as a result of an improvement in cost ratio



- Enhanced lineup of clinical chemistry products for Asia, including China
 - ▶ In October, under its own brand Sysmex will begin selling Furuno's instruments to small-scale hospitals and JEOL's instruments to medium-sized and larger hospitals
 - ▶ Sysmex will manufacture reagents in China (Wuxi) and Japan
- Sysmex began providing IDEXX, the leader in pet diagnostics, with automated hematology analyzers and reagents for animals on an OEM basis
 - ▶ Commencement of sales in July in North America, gradually expanding to a global basis



Automated hematology analyzer for animals
(ProCyte Dx, IDEXX's brand name)

- Establishment of subsidiary in fast-growing Vietnam
 - ▶ In April, commenced direct sales and support business in central and southern Vietnam, and distributor support in the north
- Established groupwide long-term environmental objectives
 - ▶ Promote global warming countermeasures, effective use of resources and waste reduction, as well as other measures

● Changed method of accounting for royalty income received

- ▶ Began recording royalty income within net sales rather than in non-operating income
 - Royalty received from overseas subsidiaries recorded as inter-area transfers in Japan region (¥0.44 billion)

● Application of accounting standard for asset retirement obligations

- ▶ Reduced both operating income and ordinary income by ¥7 million
- ▶ Reduced income before income taxes and minority interests by ¥0.19 billion

● Newly included in scope of consolidation

- ▶ Subsidiary in Spain (Established in January), HITADO (Germany, Established in January), Subsidiary in Vietnam (Established in April)

Net Sales by Geographic Region



● **Net Sales by Geographic Region**
(Sales to Customers)

(First Quarters Ended June 30)

(Billions of yen)

		FY2011 1Q		FY2010 1Q		Growth	
			Ratio		Ratio	(Yen)	(Local currency)
Net Sales		27.8	100%	24.9	100.0%	111.6%	—
Region	Americas	6.3	22.7%	5.4	22.0%	115.1%	121.8%
	Europe	8.4	30.4%	9.0	36.2%	93.6%	106.1%
	China	3.9	14.2%	2.1	8.4%	188.1%	198.6%
	AP	1.4	5.1%	1.1	4.4%	128.7%	128.7%
	Japan*	7.6	27.6%	7.2	28.9%	106.5%	106.5%

* Includes South Korea, Taiwan, Mongolia and other countries

● **Exchange Rates**

(First Quarters Ended June 30)

(Yen)

	FY2011 1Q	FY2010 1Q
1US\$	92.0	97.3
1EUR	117.0	132.6
1RMB	13.5	14.3
1SG\$	66.1	66.1

Note: For further details, please refer to the "Financial Data" section of the Sysmex website.



Note: Assumed exchange rates for the fiscal year ending March 31, 2011 are
US\$1.00 = ¥90 and €1,00 = ¥125

Geographic Segment Information: Americas



	(First Quarters Ended June 30)		(Billions of yen)
	FY2011 1Q	FY2010 1Q	% over a Year Earlier
Net Sales	6.3	5.4	115.1%
Operating Income	0.68	0.26	260.2%

Note: On a local currency basis: Net Sales, 121.8%; Operating Income, 275.2%




- **Despite the negative effects of yen appreciation, sales and income increased drastically.**
- **North America: In the hematology field, sales to integrated healthcare networks (IHNs) and commercial labs increased.**
- **Central and South America: Income decreased, owing to the reduced number of bit. Hemostasis demand increased.**
- **Promotion of direct sales in North America and growth in reagent sales prompted a substantial increase operating income.**

Geographic Segment Information: Europe




	(First Quarters Ended June 30)		(Billions of yen)
	FY2011 1Q	FY2010 1Q	% over a Year Earlier
Net Sales	8.4	9.0	93.6%
Operating Income	1.2	1.1	101.5%

Note On a local currency basis: Net Sales, 106.1%; Operating Income, 115.0%



- **In hematology, sales remained robust in five major countries (also, recoveries in Italy and Spain).**
- **Other European countries:**
 - ▶ **Denmark:** Won large-scale bid in hematology field.
 - ▶ **Greece:** Affected to certain extent by government healthcare spending.
- **The expansion of direct sales and increase in reagent sales pushed up operating income.**



Geographic Segment Information: China





	(First Quarters Ended June 30)		(Billions of yen)
	FY2011 1Q	FY2010 1Q	% over a Year Earlier
Net Sales	3.9	2.1	188.1%
Operating Income	0.92	0.48	191.6%

Note: On a local currency basis: Net Sales, 198.6%, Operating Income, 202.4%

In line with expanding healthcare demand, sales in hematology, hemostasis and urinalysis fields increased substantially.

- ▶ In hematology, promoted upgrade purchases (including upgrades from instruments capable of measuring three types of white blood cells to ones that measure five).
- ▶ In urinalysis, demand for systematization increased.
- ▶ In hemostasis, demand especially in small and medium-sized markets increased.

Operating income increased, owing to major expansion in instrument and reagent sales.




Geographic Segment Information: AP




	(First Quarters Ended June 30)		(Billions of yen)
	FY2011 1Q	FY2010 1Q	% over a Year Earlier
Net Sales	1.4	1.1	128.7%
Operating Income	0.19	0.16	115.6%

Note: On a local currency basis: Net Sales, 128.7%; Operating Income, 115.6%



- Oceania:** Won major bid in Australia, and sales increased, centered on hematology systems.
- Southeast Asia:** Sales increased, owing to ongoing market growth in Indonesia and higher sales in Malaysia.
- Operating income increased, owing to higher sales.**




Geographic Segment Information: Japan



		(First Quarters Ended June 30)		(Billions of yen)
		FY2011 1Q	FY2010 1Q	% over a Year Earlier
Net Sales		15.1	13.3	113.8%
Sales to Customers	Japan	7.1	6.7	105.2%
	South Korea, Taiwan, Mongolia and other Countries	0.57	0.45	126.1%
Intra-Area Transfers		7.4 <small>Includes royalties: ¥0.44 billion</small>	6.1	122.4%
Operating Income (Loss)		0.42	- 0.47	—

- **Japan:**
 - ▶ Promoted solution-based proposals.
 - ▶ In immunology field, sales increased due to expanded reagent portfolio.
- **South Korea, Taiwan:**
 - ▶ Sales increased centered on urinalysis systems.
- **Income grew as a result of changes in intragroup transaction prices, higher sales to Group affiliates (overseas) and change in method of accounting for royalty income.**



(First Quarters Ended June 30)

- Intra-Area Transfers: Exports to Group Affiliates, others
- Sales to Customers: South Korea, Taiwan, Mongolia, Others
- Sales to Customers: Japan
- Operating Income

Consolidated Earnings Forecast

(Unchanged from forecast announced in May 2010)



Consolidated Earnings Forecast for the Year Ending March 31, 2011

■ Net Sales: ¥125 billion
 ● Operating Income: ¥17 billion
 ● Net Income: ¥10.8 billion
● Operating Margin: 13.6%
 ● Net Income Margin: 8.6%


Planned Investment

● Capital Expenditure: ¥6.0 billion
 ● Depreciation and Amortization: ¥7.0 billion
 ● R&D Expenditure: ¥12.1 billion

Assumed exchange rates: US\$1.00 = ¥90 €1.00 = ¥125

(Billions of yen)

(Exchange rates in preceding fiscal year: US\$1.00 = ¥92.9 €1.00 = ¥131.2)



We Believe the Possibilities.

Sysmex Corporation

Contact:

IR & Corporate Communication Div.

Phone: +81-7878-265-0500

Email: info@sysmex.co.jp

URL: www.sysmex.co.jp